Laddar...

Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer

BACKGROUND: The clinical benefit of gemcitabine, the standard systemic therapy of pancreatic cancer (PaCa), remains modest as a result of high chemoresistance. The proteasome inhibitor bortezomib has antitumour activity against PaCa in vitro and in vivo. We examined the antitumour activity of combin...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Awasthi, Niranjan, Schwarz, Margaret A, Schwarz, Roderich E
Materialtyp: Artigo
Språk:Inglês
Publicerad: Blackwell Publishing Ltd 2009
Ämnen:
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2785956/
https://ncbi.nlm.nih.gov/pubmed/20495713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1477-2574.2009.00109.x
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!